Vitrolife Group (VITR) Q3 2026 earnings summary

Executive summary

• Q3 net sales reached SEK 884m, up 6% YoY and 6% organically excluding exited NACE and GPDx businesses; Technologies grew 21%.

• EBITDA rose to SEK 279m, with a 31.6% margin; net income was SEK 124m and EPS SEK 0.94, versus SEK 0.75.

Financial highlights

• Gross income was SEK 523m and gross margin 59.2%, up from 58.9%; a SEK 9m U.S. tariff refund supported margin, while higher material costs weighed.

• Operating income was SEK 178m versus SEK 144m; EBITA margin rose to 28.9% from 27.6%.

• Operating expenses fell SEK 3m YoY to SEK 345m; restructuring savings were offset by higher bad-debt provisions and inflation-driven salary increases.

• 9M sales were SEK 2,548m, flat in SEK, with 4% organic growth and a -3% currency impact; 9M EBITDA rose to SEK 825m from SEK 753m.

Outlook and guidance

• Global IVF cycles are expected to grow at a mid-single-digit rate in coming years, supported by improving reimbursement, coverage and policy.

• 2027 is expected to be a record year for product launches by number and scale; rollout will be regional, and revenue impact will take time.

• Restructuring remains on plan, with most actions completed by end-Q3 and targeted annualised savings of SEK 65m at full run rate; some savings are reinvested.

• Q4 consumables growth is expected to return to normal levels after distributor-order timing affected Q3; the prior-year comparison is strong for Technologies.

• Long-term objectives are organic growth above 10%, EBITDA margin above 33% and net debt/EBITDA below 3.